Phase 1 trial of Anvirzel™ in patients with refractory solid tumors

Investigational New Drugs

Volumn 24, Issue 5, 2006, Pages 423-427

  Mekhail, Tarek ^a   Kaur, Hanspreet ^b   Ganapathi, Ram ^a   Budd, G Thomas ^a   Elson, Paul ^a   Bukowski, Ronald M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Advanced malignancy; Antineoplastic activity; Cardiac glycosides; Oleandrin

Indexed keywords

ANVIRZEL; NERIUM OLEANDER EXTRACT;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATRIOVENTRICULAR BLOCK; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; ECG ABNORMALITY; ERYTHEMA; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEART LEFT VENTRICLE HYPERTROPHY; HEART PALPITATION; HUMAN; INJECTION SITE PAIN; KIDNEY CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; MEDICINAL PLANT; NAUSEA; NERIUM; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RIGOR; SOLID TUMOR; THYROID CARCINOMA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARDENOLIDES; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS;

EID: 33745013348     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-7772-x     Document Type: Article

References (11)

1. Langford SD, Boor PJ (1996) Oleander toxicity: An examination of human and animal toxic exposures. Toxicology 109(1):1-13
2. Manna SK, Sah NK, Newman R, Cismerps A, Aggarwal BB (2000) Oleandrin suppresses activation of nuclear transcription of factor-B, activator protein-2 and c-Jun NH2-terminal kinase. Cancer Res 60:3838-3847
3. Abe F, Yamaguchi T (1978) Digitoxigenin oleandroside and 5α-Adynerin in the leaves of Nerium odorum. Chem Pharm Bull 26:3023-3027
4. Abe F, Yamaguchi T (1979) Oleasides-novel cardenolies with an unusual framework on Nerium. Chem Pharm Bull 27:1604-1610
5. Wang X, Plomley JB, Newman RA, Cisneros A (2000) LC(MS(MS analyses of an oleander extract for cancer treatment. Anal Chem 72(15):3547-3552
6. Smith JA, Madden T, Vijjeswarapu M, Newman RA (2001) Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU 145 by Anvirzel and its cardiac glycoside component, oleandrin. Biochem Pharmacol 62(4):469-472
7. Jortani SA, Helm RA, Valdes R (1996) Inhibition of Na,K-ATPase by oleandrin and oleandrigenin, and their detection by digoxin immunoassays. Clin Chem 42:1654-1658
8. Pathak S, Multani AS, Narayan S, Kumar V, Newman RA (2000) Anvirzel, an extract of Nerium oleander, induces cell death in human but not murine cancer cells. Anticancer Drugs 11(6):455-463
9. McConkey DJ, Lin Y, Nutt LK, Ozel HZ, Newman RA (2000) Cardiac glycosides stimulate Ca increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res 60(14):3807-3812
10. WHO (1979) Handbook for Reporting Results for Cancer Therapy. WHO, Geneva
11. Gupta A, Joshi P, Jortani SA, Valdes R Jr, Thorkelsson T, Verjee Z, Shemie S (1997) A case of nondigitalis cardiac glycoside toxicity. The Drug Monit 19(6):711-714